

NEUROFIBROMATOSIS MIDWEST

ST. CHARLES, ILLINOIS

FINANCIAL STATEMENTS

SEPTEMBER 30, 2024

TABLE OF CONTENTS

	<u>PAGE</u>
INDEPENDENT ACCOUNTANT’S REVIEW REPORT	1
FINANCIAL STATEMENTS	
Statement 1 – Statement of Financial Position	3
Statement 2 – Statement of Activities and Net Assets	4
Statement 3 – Statement of Functional Expenses	5
Statement 4 – Statement of Cash Flows	6
NOTES TO FINANCIAL STATEMENTS	7



KOLNICKI



PETERSON



WIRTH

INDEPENDENT ACCOUNTANT'S REVIEW REPORT

Board of Directors
Neurofibromatosis Midwest
St. Charles, Illinois

We have reviewed the accompanying financial statements of Neurofibromatosis Midwest (a nonprofit organization), which comprise the statement of financial position as of September 30, 2024, and the related statements of activities and net assets, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement whether due to fraud or error.


Accountant's Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

We are required to be independent of Neurofibromatosis Midwest and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements related to our review.

Accountant's Conclusion

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.



KOLNICKI, PETERSON, WIRTH LLC
Certified Public Accountant

Downers Grove, Illinois
May 20, 2025

**NEUROFIBROMATOSIS MIDWEST
STATEMENT OF FINANCIAL POSITION
SEPTEMBER 30, 2024**

CURRENT ASSETS	
Cash and cash equivalents	\$ 67,656
Investments	<u>294,756</u>
Total current assets	<u>362,412</u>
PROPERTY & EQUIPMENT	
Furniture and equipment	4,283
Less accumulated depreciation	<u>(1,525)</u>
Net property and equipment	<u>2,758</u>
OTHER ASSETS	
Security deposit	<u>1,100</u>
Total other assets	<u>1,100</u>
Total assets	<u><u>\$ 366,270</u></u>
CURRENT LIABILITIES	
Accrued expenses	<u>\$ 951</u>
Total current liabilities	<u>951</u>
NET ASSETS	
Without donor restrictions	<u>365,319</u>
Total net assets	<u>365,319</u>
Total liabilities and net assets	<u><u>\$ 366,270</u></u>

See independent accountant's review report
and notes to the financial statements

**NEUROFIBROMATOSIS MIDWEST
STATEMENT OF ACTIVITIES AND NET ASSETS
FOR THE YEAR ENDED SEPTEMBER 30, 2024**

	Without Donor Restrictions	With Donor Restrictions	Total
REVENUES			
Special events	\$ 87,939	\$ -	\$ 87,939
Contributions	207,630	-	207,630
Unrealized gains on investment	17,603	-	17,603
Other income	12,096	-	12,096
Total revenue	<u>325,268</u>	<u>-</u>	<u>325,268</u>
EXPENSES			
Program services	197,646	-	197,646
Management and general	28,768	-	28,768
Fundraising	26,259	-	26,259
Total expense	<u>252,673</u>	<u>-</u>	<u>252,673</u>
Change in net assets	72,595	-	72,595
Net assets, beginning of year	<u>292,724</u>	<u>-</u>	<u>292,724</u>
Net assets, end of year	<u>\$ 365,319</u>	<u>\$ -</u>	<u>\$ 365,319</u>

See independent accountant's review report
and notes to the financial statements

**NEUROFIBROMATOSIS MIDWEST
STATEMENT OF FUNCTIONAL EXPENSES
FOR THE YEAR ENDED SEPTEMBER 30, 2024**

EXPENSES	<u>Program Services</u>	<u>Management & General</u>	<u>Fundraising</u>	<u>Total Expenses</u>
Academic Scholarship/Camp	\$ 16,400	\$ -	\$ -	\$ 16,400
Grants and awards	1,500	-	-	1,500
Wages	98,046	16,995	15,687	130,728
Payroll taxes	6,801	1,600	1,600	10,001
Accounting	1,430	-	1,320	2,750
Lobbying	10,350	-	-	10,350
Program	10,141	-	-	10,141
Advertising and promotion	198	-	-	198
Office expenses	6,712	1,138	1,138	8,988
Information technology	7,975	1,501	2,081	11,557
Occupancy	9,595	4,798	1,599	15,992
Travel	8,344	-	-	8,344
Conferences and meetings	300	-	-	300
Payments to affiliates	12,689	-	-	12,689
Depreciation	857	-	-	857
Insurance	1,882	311	207	2,400
Bank and credit fees	2,368	2,099	2,301	6,768
Telephone	1,520	326	326	2,172
NF education	481	-	-	481
Miscellaneous	57	-	-	57
Total expenses	<u><u>\$ 197,646</u></u>	<u><u>\$ 28,768</u></u>	<u><u>\$ 26,259</u></u>	<u><u>\$ 252,673</u></u>

See independent accountant's review report
and notes to the financial statements

**NEUROFIBROMATOSIS MIDWEST
STATEMENT OF CASH FLOWS
SEPTEMBER 30, 2024**

CASH FLOWS FROM OPERATING ACTIVITIES	
Increase in net assets	\$ 72,595
Adjustments to reconcile increase in net assets to net cash provided by operating activities:	
Depreciation	857
Unrealized gain on investments	(17,603)
Changes in operating assets and liabilities:	
Decrease in other current assets	105
Increase in accrued expenses	<u>77</u>
Net cash provided by operating activities	<u>56,031</u>
CASH FLOWS FROM INVESTING ACTIVITIES	
Purchase of investments	<u>(39,945)</u>
Net cash used by investing activities	<u>(39,945)</u>
NET INCREASE IN CASH AND CASH EQUIVALENTS	16,086
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	<u>51,570</u>
CASH AND CASH EQUIVALENTS, END OF YEAR	<u><u>\$ 67,656</u></u>

See independent accountant's review report
and notes to the financial statements

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 1 – NATURE OF ORGANIZATION

Neurofibromatosis Midwest (the Organization) is a not-for-profit organization incorporated under the laws of Illinois, and established exclusively for charitable purposes. The Organization provides people with neurofibromatosis, and their families, with information about the disorder and helps them locate medical, social and genetic counseling. The Organization acts as an information source for physicians, health workers and the general public on neurofibromatosis and related disorders, and stimulates and supports scientific research on the cause, prevention and treatment of neurofibromatosis.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accounting policies of Neurofibromatosis Midwest conform to the generally accepted accounting policies. The following is a summary of the more significant policies.

Basis of Accounting

The financial statements of the Organization are prepared on the accrual basis of accounting and accordingly reflect all significant receivables, payables, and other liabilities. Under the accrual basis, contribution revenue is recognized when the Organization is notified of the existence of a pledge or receives a contribution. The contributions are recognized as income in the period to which they relate. Expenses are recognized in the period in which the related liability is incurred.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The Organization's management believes that the estimates and assumptions are reasonable in the circumstances; however, the actual results could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents consist of deposits in federally insured accounts, which are short term, interest bearing, highly liquid with maturities of three months or less. The balances are insured by the Federal Deposit Insurance Corporation up to \$250,000. At September 30, 2024, the Organization's deposits did not exceed federally insured limits.

Pledges Receivable

Pledges receivable are presented at the fair value of the promises and are estimated by management to be fully collectable.

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

Donated Services

Contributions of services are recognized if the services received (a) create or enhance nonfinancial assets or (b) require specialized skills, are provided by people with those skills, and would otherwise be purchased by the Organization. During the year ended September 30, 2024, the value of contributed services meeting the requirements for recognition in the financial statements was not material and has not been recorded.

Income Taxes

The Internal Revenue Service has ruled that the Organization is exempt from the payment of federal income tax under the provisions of Section 501(c)(3) of the Internal Revenue Code as an educational and charitable organization.

The Organization's income tax filings are subject to audit by various taxing authorities. The Organization's open audit periods are 2021 through 2023.

Management has determined that the Organization has no unrelated business income for the year ended September 30, 2024, and, therefore no provisions for federal or state income taxes has been made.

Net Assets

The Organization reports information regarding its financial position and activities according to two classes of net assets that are based upon the existence or absence of restrictions on use that are placed by its donors: net assets without donor restrictions and net assets with donor restrictions.

Net assets with donor restrictions are subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, such as those that the donor stipulates those resources be maintained in perpetuity.

Net assets without donor restrictions are resources available to support operations and not subject to donor restrictions. The only limits on the use of net assets without donor restrictions are the broad limits resulting from the nature of the Organization, the environment in which it operates, the purposes specified in its corporate documents and its application for tax-exempt status, and any limits resulting from contractual agreements with creditors and others that are entered into in the course of its operations.

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

Investments

The Organization is required to provide additional information in the financial statements, based on the implementation of the FASB Accounting Standards Codification FASB (ASC) No. 820-10-35-1: *Fair Value Measurements and Disclosures*. This Standard defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurement.

Property and Equipment

Property and equipment are recorded at cost or at estimated fair value at date of donation. Depreciation is recorded over the estimated useful lives of the related asset using the straight-line and accelerated methods over recovery periods allowable under income tax regulations. The estimated useful lives of property and equipment for purposes of computing depreciation are:

Furniture and equipment	5 years
-------------------------	---------

Depreciation expense for the year ended September 30, 2024 was \$857.

Functional Allocation of Expenses

The costs of providing various programs and other activities have been summarized on a functional basis in the Statement of Activities and Net Assets and the Statement of Functional Expenses. Expenses that can be identified with a specific program or support service are charged directly to that program or support service. Costs common to multiple functions have been allocated among the functions identified.

Management and general expenses include those costs that are not directly identifiable with any specific program, but which provide for the overall support and direction of the Organization.

Fundraising costs are expensed as incurred, even though they may result in contributions received in future years.

Advertising

The Organization expenses advertising costs as incurred. Advertising expense for the year ended September 30, 2024 was \$198.

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)**Date of Management Review**

Subsequent events were evaluated through the date of this report and the date the financial statements were available to be issued was May 20, 2025. No subsequent events have been identified that are required to be disclosed through that date.

NOTE 3 – INVESTMENTS

Investments consist of the following:

	September 30, 2024	
	Cost	Market
Brokerage account:		
Mutual funds	\$ 235,521	\$ 294,756
Totals	\$ 235,521	\$ 294,756

The following schedules summarizes the investment return and its classification in the statement of activities for the year ended September 30, 2024:

Dividends and interest	\$ 7,144
Unrealized gain	17,603
Investment gain	1,483
Total return on investments	\$ 26,230

NOTE 4 – CONCENTRATIONS OF CREDIT RISK

The Organization maintains its investments in a brokerage firm. The balances are insured by the Securities Investor Protection Corporation up to \$500,000. At September 30, 2024, the Organization's uninsured balance was zero.

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 5 – FAIR VALUE MEASUREMENTS

FASB Accounting Standards Codification (ASC) No. 820-10-35-1: Fair Value Measurement and Disclosure establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy consists of three broad levels: Level 1 inputs consist of unadjusted quoted prices in active markets for identical assets and have the highest priority. The Organization uses appropriate valuation techniques based on the available inputs to measure the fair value of its investments. When available, the Organization measures fair value using Level 1 inputs because they generally provide the most reliable evidence of fair value. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly. Observable inputs are those that reflect the assumptions market participants would use in pricing the asset developed on market data. Level 2 inputs were only used when Level 1 inputs were not available.

Level 2 fair measurements: the fair value of mutual funds is based on quoted net asset values of the shares held by the Organization at year end.

The Organization's assets recorded at fair value have been categorized based upon a fair value hierarchy in accordance with FASB (ASC) No. 820-10-35-1.

	Significant Other Observable Inputs (Level 2)	Balance as of Sept. 30, 2024
Assets		
Investments in mutual funds, at fair value	\$ 294,756	\$ 294,756

NOTE 6 – LEASE AGREEMENTS

The Organization leases its current office space under an operating lease which was renewed until January 31, 2025. This lease calls for base monthly payments of \$1,220. Total rent expense under this lease was \$14,518 for 2024. Future minimum lease payments are as follows:

2025	\$ 4,880
Total	\$ 4,880

NOTE 7 – CASH FLOW INFORMATION

The Organization paid no cash for interest or income taxes during 2024.

**NEUROFIBROMATOSIS MIDWEST
NOTES TO FINANCIAL STATEMENTS
SEPTEMBER 30, 2024**

NOTE 8 – LIQUIDITY AND AVAILABILITY OF FINANCIAL ASSETS

The following reflects the Organization’s financial assets as of the balance sheet date, reduced by amounts not available for general use because of contractual, board, or donor-imposed restrictions within one year of the balance sheet date.

Cash and cash equivalents	\$ 67,656
Investments	<u>294,756</u>
 Total financial assets available for general expenditures within one year	 <u>\$ 362,412</u>

This information is an integral part
of the accompanying financial statements